restorex_logo-h-200, is the world's first polymer-based technology platform designed to enable heart valve restoration - through ETR

ETR

Endogenous Tissue Restoration (ETR) is a new therapeutic approach, enabling the patient’s own body to naturally restore a new heart valve.

With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ heart valve, forming a new, natural and fully functional valve within it. As ETR occurs, Xeltis implants are gradually absorbed by the body.

ETR is enabled by bioabsorbable polymers based on Nobel Prize awarded science.

ETR in Action

Step 1

Xeltis devices work as normal heart valves or blood vessels once implanted.

Step 1
Step 2

New tissue forms around and inside the device to develop a new, healthy, functioning heart valve.

Step 2
Step 3

Xeltis devices are designed to absorb over time, leaving patients with a new, healthy, functioning heart valve.

Step 3

restorex_logo-h-200 

RestoreX is the world's first polymer-based technology designed to enable natural restoration of heart valve function, through a therapeutic approach called Endogenous Tissue Restoration (ETR). ETR is enabled by bioabsorbable polymers based on Nobel Prize awarded science.

No in vitro tissue engineering

No stem cells

No biological agents

No animal tissue

Electrospinning
supramolecular polymers

Using electric force to draw supramolecular polymer solutions into threads that measure a fraction of the diameter of a hair.

20+ international
patent families portfolio
protecting Xeltis’ innovative supramolecular polymer platform and its electrospinning methodology for device manufacturing.

100,000s+ patients
with cardiovascular conditions requiring heart valve replacements potentially addressed with RestoreX technology.

Product Pipeline

restorex_logo-h-200 Technology Outstanding 2-year clinical data at EACTS
In Vitro
Pre-Clinical
Clinical
Pulmonary Heart Valve First commercial product
In Vitro
Pre-Clinical
Clinical
Aortic Heart Valve Extending pipeline to high pressure circuit
In Vitro
Pre-Clinical
Clinical
Additional Applications Further pipeline expansion underway
In Vitro
Pre-Clinical
Clinical
In Vitro
Pre-Clinical
Clinical

Presented Data

2017
TCT 2017 annual meeting:
12-month preclinical data on aortic heart valve
EuroPCR 2017 annual meeting:
6-month preclinical data on aortic heart valve View PDF
7th World Congress of Pediatric Cardiology & Cardiac Surgery (WCPCCS):
Xeltis 31-month feasibility clinical trial data of a novel bioabsorbable vascular graft in modified Fontan procedure View PDF
2016
30th European Association for Cardio-Thoracic Surgery (EACTS) annual meeting:
Xeltis 2-year feasibility clinical trial data of a novel bioabsorbable vascular graft in modified Fontan procedure - mid-term results View PDF
30th European Association for Cardio-Thoracic Surgery (EACTS) annual meeting:
Xeltis 1-year in vivo data of a novel bioabsorbable pulmonary heart valved conduit
96th American Association for Thoracic Surgery (AATS) annual meeting: Xeltis 1-year feasibility clinical trial data showed significant improvement in patients’ general conditions. View PDF
3rd Heart Valve Society (HVS) annual meeting: Xeltis 1-year feasibility clinical trial data show significant improvement in patients’s general conditions. View PDF
10th World Biomaterials Congress (WBC) annual meeting: Preclinical data on ETR validated potential of Xeltis technology to “guide the restoration of a patient’s natural tissue into a functional living vascular replacement.” View PDF

Nobel
Prize-Awarded Science

Jean-Marie Lehn, Nobel Laureate Awarded 1987 Nobel Prize in Chemistry for pioneering supramolecular chemistry, the science at the basis of Xeltis’ technology.
“Supramolecular chemistry enables Xeltis technology by providing unique biochemical and biomechanical properties, delivering solutions to issues faced by traditional materials over the course of decades.” Professor Lehn is a Scientific Advisor to Xeltis.
RestoreX technology platform comprises investigational devices that are not available for sale.